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Abstract
Background: Previous studies indicate that clinical guidelines using combined risk evaluation for
cardiovascular diseases (CVD) may overestimate risk. The aim of this study was to model and
discuss implementation of the current (2007) hypertension guidelines in a general Norwegian
population.
Methods: Implementation of the current European Guidelines for the Management of Arterial
Hypertension was modelled on data from a cross-sectional, representative Norwegian population
study (The Nord-Trøndelag Health Study 1995-97), comprising 65,028 adults, aged 20-89, of whom
51,066 (79%) were eligible for modelling.
Results: Among individuals with blood pressure ≥120/80 mmHg, 93% (74% of the total, adult
population) would need regular clinical attention and/or drug treatment, based on their total CVD
risk profile. This translates into 296,624 follow-up visits/100,000 adults/year. In the Norwegian
healthcare environment, 99 general practitioner (GP) positions would be required in the study
region for this task alone. The number of GPs currently serving the adult population in the study
area is 87 per 100,000 adults.
Conclusion: The potential workload associated with the European hypertension guidelines could
destabilise the healthcare system in Norway, one of the world's most long- and healthy-living
nations, by international comparison. Large-scale, preventive medical enterprises can hardly be
regarded as scientifically sound and ethically justifiable, unless issues of practical feasibility,
sustainability and social determinants of health are considered.
Background
The interest in preventive measures for cardiovascular dis-
eases (CVD) has escalated in the last decades [1]. Apart
from smoking and elevated cholesterol, hypertension has
for the last fifty years been considered the most predictive
CVD risk factor. The first international report highlighting
the importance of blood pressure control was published
in 1962 by the World Health Organisation (WHO) [2].
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clinical hypertension guidelines have followed on both
sides of the Atlantic [3-13]. In 2003, the European Society
of Hypertension (ESH) and the European Society of Car-
diology (ESC) published their own guidelines on hyper-
tension treatment, having until then endorsed the
guidelines issued by the WHO and the International Soci-
ety of Hypertension (ISH) [9]. The 2003 hypertension
guidelines became the most quoted paper in the medical
literature [13], and the guidelines were updated in 2007
[13].
For the last decade, combined CVD risk evaluation instru-
ments have gained an important role in CVD prevention
guidelines [8,12,14-16]. First prominent in the 1999
guidelines from the WHO/ISH [4], and followed by the
2003 [9] and 2007 [13] publications by the ESH/ESC,
such estimates have also become central in hypertension
guidelines. During the same time period, however, the
threshold for intervention in relation to individual risk
factors has also been lowered. The 2007 ESH/ESC guide-
lines also present a new risk factor, high pulse pressure
(systolic minus diastolic blood pressure) in the elderly, in
its combined risk model.
To be implementable in the everyday clinical setting, it is
essential that guidelines harmonise with clinical and prac-
tical realities. Both the number of patients in need of treat-
ment and the treatment goals should appear reasonable,
both from a societal and a local clinical perspective. When
the approach of guidelines to CVD risk identification and
stratification changes, it is hard to foresee the conse-
quences in terms of the population-at-risk and the clinical
workload. One way to address this important topic would
be to conduct modelling studies as an integral part of
guideline development. Empirical modelling studies of
clinical guidelines, however, are surprisingly rare. Some
recent papers [17-20], including studies from our own
group [21] have shown that the 2003 European Guide-
lines on CVD Prevention [8] significantly overestimated
CVD risk in several European regions. Consequently,
there is a strong argument for assessing the potential
impact of new clinical guidelines.
The aim of the present study was to model the implica-
tions of the most recent European guidelines for the man-
agement of arterial hypertension [13] in a general
Norwegian population. We primarily estimated the prev-
alence of individuals with unfavourable CVD risk levels
according to the guidelines. Subsequently, the potential
clinical workload and workforce associated with reaching
recommended treatment goals in this group were calcu-
lated. We finally reflect upon the implications of our find-
ings.
Methods
Data from a large and renowned population study (the
HUNT 2 Study, see http://www.ntnu.no/hunt/english)
[22] allowed us to calculate the proportion of the popula-
tion with an unfavourable combination of risk factors, as
defined by the 2007 guidelines [13]. Based on these fig-
ures, we estimated the number of follow-up visits needed
to achieve the guidelines' recommended treatment goals.
This number was again translated into the number of gen-
eral practitioners (GP) potentially needed to carry out this
work.
Norway is a country with a solid primary healthcare sys-
tem, and every citizen is listed with a GP. Care is mostly
delivered by the GPs and rarely by other trained staff, such
as nurse practitioners. Our model was designed to fit into
this context. In the following, we will present some essen-
tial details about the HUNT 2 data and our modelling of
the clinical workload associated with the 2007 guidelines.
The HUNT 2 population data
The Nord-Trøndelag Health Study 1995-97 (HUNT 2) has
been described in detail elsewhere [22]. The overall partic-
ipation rate in HUNT 2 was 76% among women and 67%
among men. The HUNT 2 population has been consid-
ered representative of the total Norwegian population
regarding demography, socio-economic factors, morbid-
ity and mortality, including mortality from CVD [22].
Our model is based on data from all HUNT 2 participants
aged 20-89 years, in total 65,028 individuals (30,447
males and 34,581 females), see Table 1.
Of these, 12,139 individuals (3,085 men and 9,054
women) had to be excluded because they had blood pres-
sure levels below 120/80 mmHg (the 2007 guidelines do
not address this group). Additionally, 1,015 men and 808
women had missing data regarding blood pressure or
other factors of the six risk factors considered. In total, this
rendered 51,066 HUNT 2 participants (79%) eligible for
our modelling procedure. Among the 13,962 excluded
participants, however, 788 (5.6%) did report established
CVD, diabetes or receiving blood-pressure-lowering treat-
ment. Our study thus underestimates the population-in-
need-of-attention and associated workload at this point.
The participation rates in the HUNT 2 study were different
in different age groups, with lower rates among the
younger participants. When estimating the annual
number of follow-up visits, this unequal participation rate
was corrected for by age-standardising the HUNT 2 data
with the 2007 age distribution in Nord-Trøndelag, which
is similar to Norway in general [23,24]. This gives the
younger age-groups, and hence the lower risk levels,
increased weight in our calculations.Page 2 of 9
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The basis for our model is the definition and classification
of blood pressure levels, as defined by the guidelines, see
Figure 1. The determination of an individuals' risk level
however also depends on the presence of other relevant
risk factors. Figure 2 gives an overview of these, including
the cut-off points applied in our modelling procedure.
In the present dataset, smoking was defined as daily
smoking of cigarettes, cigars or a pipe. Family history of
CVD was defined as 1st-degree relatives (parents, brothers
and/or sisters) with myocardial infarction before age 60 or
stroke at any age. Established CVD was defined as self-
reported myocardial infarction, stroke or angina pectoris.
Methods for measurement of blood pressure and body
composition are described elsewhere [22].
Some risk factors listed in the guidelines had to be omit-
ted from our model as they were not assessed in the
HUNT 2 study. These were: abnormal glucose tolerance
test, fasting plasma glucose, LDL-cholesterol and triglycer-
ide levels (HUNT 2 participants were not fasting). People
with renal disease and/or subclinical organ damage were
not accounted for separately.
The 2007 guidelines give no details regarding the cut-off
points for 'levels of pulse pressure (in the elderly)'. After
reviewing the literature, we defined 'elderly' as above 55
years of age (the same definition as the guidelines used for
age as an independent risk factor in men) and 'high' pulse
pressure level as ≥60 mmHg [25-35].
Estimation of clinical workload
Our estimates of the clinical workload related to each
CVD risk category have been inserted in Figure 1. The
number of follow-up visits are based on the guidelines'
specific recommendations [13], when possible. As the fol-
low-up frequency is not always accurately specified, we
needed to make some interpretations, which we justify in
detail below.
- Individuals at the lowest risk level (called 'average
risk') are said to need no blood pressure intervention,
and therefore we set the number of yearly visits to zero
for this category.
- The guidelines' Box 22 ('Patients' follow-up', p.
1513) states that "Patients at low risk or with grade 1
hypertension may be seen every 6 months...". We
therefore use 2 visits per year for these categories.
- The guidelines subsequently state that "Visits should
be more frequent in high or very high risk patients.
This is the case also in patients under non-pharmaco-
logical treatment alone due to the variable antihyper-
tensive response and the low compliance with this
intervention". We defined the term "more frequent"
(than 2 visits per year) to mean 3-4 visits per year.
Based on the above quote, we allocated an average of
3.5 visits per year for the categories 'high added risk,'
'very high added risk' and individuals with 'low added
risk' who exhibit BP <140/90 under non-pharmaco-
logical surveillance due to the presence of other risk
factors.
Since the choice of 3.5 visits per year on average for the
most demanding follow-up categories can be discussed,
we analysed our model's sensitivity to changes regarding
this number. Alternative analyses based on 3.0 and 4.0
visits per year are also presented.
Table 1: Participants in the study
Age groups Participants in HUNT-2 Eligible
Men Women Total Men Women Total
20-24 1761 2156 3917 1293 1085 2378
25-29 2163 2561 4724 1703 1202 2905
30-34 2579 2917 5496 2085 1362 3447
35-39 2820 3207 6027 2315 1645 3960
40-44 3161 3478 6639 2670 2140 4810
45-49 3334 3566 6900 2920 2520 5440
50-54 3064 3314 6378 2748 2631 5379
55-59 2333 2461 4794 2121 2086 4207
60-64 2113 2292 4405 1934 2057 3991
65-69 2232 2418 4650 2095 2249 4344
70-74 2134 2382 4516 1980 2240 4220
75-79 1594 2064 3658 1474 1942 3416
80-84 820 1231 2051 726 1127 1853
85-89 339 534 873 283 433 716
Total 30447 34581 65028 26347 24719 51066
Participants in the HUNT-2 (1995-7) study and those eligible for modelling in the present study according to age and gender.Page 3 of 9
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often (e.g., every 2 to 4 weeks)" [13] during the blood
pressure drug titration phase. Our model however does
not include visits needed to formally diagnose hyperten-
sion, nor the series of visits associated with initial drug
titration. As we include only follow-up visits beyond that
point, our model will underestimate workload.
As mentioned, the guidelines only address individuals
with blood pressure levels of at least 120/80 mmHg, and
people with lower blood pressure are excluded from this
model, regardless of their medical history.
Estimating the necessary primary care workforce
The prevalence of individuals assigned to each of the risk
categories outlined in Figure 2 was calculated as a basis for
analysis of clinical workforce needed.
In 2007 (January 1st), the Nord-Trøndelag County had
129,069 inhabitants. The population aged 20-89 accounts
for about 72% of the total [23]. Nord-Trøndelag County
was served by 112 GPs in 2007 [36]. This translates into
87 GPs per 100,000 inhabitants. This GP density is quite
comparable to Norway as a whole (90 GPs per 100,000
inhabitants). We estimated the same number of GPs (87)
to take care of every 100,000 adults (i.e., individuals eligi-
ble for our study). When calculating the medical work-
force needed, we assumed that each GP in Nord-
Trøndelag would conduct an average of 3000 consulta-
tions per year, which is equal to the Norwegian average
[36].
Statistics
The SPSS statistical package, version 15.0, was used for
statistical frequency analyses.
Ethical approval
The HUNT 2 survey in the Nord-Trøndelag health study
was approved by the Norwegian Data Inspectorate and
the regional committee for ethics in medical research.
Cardiovascular risk stratification chart with recommended follow-up frequency for each categoryFigure 1
Cardiovascular risk stratification chart with recommended follow-up frequency for each category. A reconstruc-
tion of Figure 1 from the 2007 Guidelines for Management of Arterial Hypertension [13], with inserted recommendations 
regarding the number of follow-up visits per year in each risk category. Low, moderate, high and very high risk refer to the 10-
year risk of a CV fatal or non-fatal event. The term 'added' indicates in all categories that risk is greater than average. The risk 
factors referred to in the left column are: age, smoking, dyslipidaemia, elevated fasting plasma glucose, abnormal glucose toler-
ance test, abdominal obesity, a family history of premature CVD and 'high pulse pressure in the elderly'. Abbreviations: SBP: 
systolic blood pressure; DBP: diastolic blood pressure; HT: hypertension. OD: subclinical organ damage; MS: metabolic syn-
drome.
Blood pressure (mmHg) 
Other risk factors, 
OD or disease 
Normal 
SBP 120-129 
or DBP 80-84 
High normal 
SBP 130-139 
or DBP 85-89
Grade 1 HT 
SBP 140-159 
or DBP 90-99
Grade 2 HT 
SBP 160-179 or 
DBP 100-109
Grade 3 HT 
SBP ≥180 
or DBP ≥110
Risk level Average risk Average risk Low 
added risk 
Moderate 
added risk 
High 
added risk No other  
risk factor Follow up 
visits /year 0 0 2 2 3.5 
Risk level Low 
added risk 
Low 
added risk 
Moderate 
added risk 
Moderate 
added risk 
Very high 
added risk 1-2 risk 
factors Follow up 
visits /year 3.5 3.5 2 2 3.5 
Risk level Moderate 
added risk 
High 
added risk 
High 
added risk 
High 
added risk 
Very high 
added risk 
3 or more  
risk factors, 
MS, OD or 
Diabetes 
Follow up 
visits /year 3.5 3.5 3.5 3.5 3.5 
Risk level Very high 
added risk 
Very high 
added risk 
Very high 
added risk 
Very high 
added risk 
Very high 
added risk Established 
CV or renal 
disease Follow up 
visits /year 3.5 3.5 3.5 3.5 3.5 Page 4 of 9
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The 2007 European Guidelines for Management of Arte-
rial Hypertension [13] covered 79% of the total HUNT 2
population, aged 20-89. Figure 3 shows age-standardised
prevalence (percentage and absolute numbers) in each
risk category, as well as the associated number of follow-
up visits recommended per 100,000 adults per year.
As shown in Figure 3, only 6.6% of all individuals with a
blood pressure of ≥120/80 mmHg were classified as "aver-
age risk". The rest, or 93.4% (i.e., 74% of the total, adult
population), were classified as eligible for regular clinical
attention and/or drug treatment in the near future, based
on their total CVD risk profile, according to guideline rec-
ommendations. In the subgroup aged 50-64, the propor-
tion eligible for clinical attention reached 99%.
Implementing the aforementioned model of clinical fol-
low-up visits to our population of 65,028 adults, we
found that 296,624 visits per 100,000 adults would be
needed per year (Figure 3). This means that 99 GPs per
100,000 adults would be needed in Nord-Trøndelag
County to implement these hypertension guidelines. This
figure can be compared with the estimated number of 87
GPs per 100,000 adults, who in 2007 served the adult
population in the county for all contact reasons.
If individuals in the higher risk categories and those under
specific lifestyle supervision were to be seen 3.0 times or
alternatively 4.0 times yearly instead of 3.5 times, as pre-
viously discussed, the total number of visits would be
260,035 or alternatively 333,212 visits per year. This cor-
responds to 87 or 111 GP positions, respectively.
Figure 4 shows the proportion of individuals at different
risk levels by age and gender. As expected, the proportion
of individuals at higher risk increases with age for both
men and women.
Discussion
Modelling the implementation of current European
guidelines on arterial hypertension [13] on a general pop-
ulation of Norwegian adults, aged 20-89, we found that
93.4% of all individuals with blood pressure of ≥120/80
mmHg (i.e., 74% of the total, adult population) would be
eligible for regular clinical attention and/or drug treat-
ment, based on their total CVD risk profile. In terms of the
primary care workforce, a larger number of GPs would be
needed for the sole purpose of implementing the hyper-
tension guidelines, than the number of doctors who cur-
rently serve all primary care needs of this population -
which is affluent as well as long-lived and healthy-living,
by international comparison. These findings raise impor-
tant questions related to the scientific validity, clinical sus-
tainability and social responsibility of the guidelines.
Some limitations and other methodological considera-
tions related to our implementation model have to be
taken into consideration. Compared with other European
regions, including regions involved in the MONICA
project (third phase, 1992-94) [37], HUNT 2 did not dif-
fer significantly with respect to cholesterol levels and
smoking habits at the time of data collection. The blood
pressure levels, however, were somewhat higher in the
HUNT 2 population than in most comparable countries,
yet lower than in Finland [37,38].
Our sensitivity analysis of 3.0 and 4.0 follow-up visits
instead of 3.5 for those in the higher risk levels and those
with lifestyle changes shows that our concerns remain
valid, even if the conservative estimate is chosen.
It would obviously have been of interest to qualify the
total workload in terms of 'additional preventive meas-
ures' as opposed to 'already established workload related
to clinical disease'. Our data are however not suited to
make valid and transparent calculations of these sub-cate-
gories of workload. For instance, we know that a good
deal of blood pressure follow-up in Norway takes place in
consultations taking place for other contact reasons.
It may be argued that follow-up of known CVD risk
patients may demand less, or alternatively more, than the
average consultation time. The guideline authors empha-
sise that blood pressure control is a demanding, clinical
task: "Indeed, health providers sometimes wrongly con-
Risk factors and cut-off pointsF gure 2
Risk factors and cut-off points. The risk factors and the 
cut-off points used in the present study, based on the 2007 
Guidelines for the Management of Arterial Hypertension 
[13]. Abbreviations: M: men; W: women; TC: total choles-
terol; MI: myocardial infarction.
Risk factors Cut-off points 
Pulse pressure in the elderly ≥ 60 mmHg in people > 55 years of age 
Age M > 55 years W > 65 years 
Smoking Daily smoking of cigarettes, 
cigars or pipe 
Dyslipidaemia TC > 5.0 mmol/l or  HDL < 1.0 mmol/l 
Abdominal obesity Waist circumference > 102 
cm (M), > 88 cm (W) 
Family history of premature 
cardiovascular disease 
Having a 1st-degree relative 
with MI before age 60 or 
stroke at any age Page 5 of 9
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few minute visits and reimburse doctors accordingly"
[13]. In the presence of doubt, we chose to base our calcu-
lations on the average Norwegian GP patient turnover
rate. These calculations are however transparent and can
easily be adapted to fit healthcare models with higher GP
turnover rates or, alternatively, more contact with auxil-
iary staff and fewer doctor visits.
The aforementioned adjustments made to accommodate
the nature of the HUNT 2 data as well as the exclusion of
visits related to initial diagnosis and drug titration, will all
tend to underestimate the population-at-risk and clinical
workload. This, however, does not mean that our final
results represent an underestimate. As said, the average
blood pressure in the HUNT 2 population was slightly
higher than in comparable countries, and the use of ten-
year-old population data in our model may also imply a
tendency to overestimation as blood pressure levels in the
Norwegian population may have decreased since 1995-7.
Such trends have at least been observed in some other
European regions [39,40]. But even if our model were to
overestimate the population-at-risk somewhat, important
theoretical, practical and ethical issues need to be
addressed.
One crucial question that is hard to answer, and which is
not specific for the 2007 hypertension guidelines, is
whether the guideline's recommended approach would
prove clinically effective if implemented in the general
population, just as recommended. We have previously
demonstrated how the 2003 European CVD prevention
guidelines inflated the high-risk group, most likely due to
a phenomenon called retrospective risk bias
[17,20,21,24,41], resulting from the fact that mortality
from CVD has decreased steadily in Western Europe dur-
ing recent decades [42]. The reasons for this decline are
Age-standardised prevalence of individuals in each risk category and associated number of follow-up visitsFigure 3
Age-standardised prevalence of individuals in each risk category and associated number of follow-up visits. Age-
standardised prevalence for each risk category in relation to blood pressure levels (absolute numbers within brackets) as well 
as the calculated number of follow-up visits needed each year according to the 2007 Guidelines for the Management of Arterial 
Hypertension [13] per 100,000 adults, aged 20 to 89 in the HUNT 2 Study, Norway. Abbreviations: OD: subclinical organ dam-
age; HT: hypertension; SBP: systolic blood pressure; DBP: diastolic blood pressure; MS: metabolic syndrome; CV: cardiovascu-
lar disease.
Blood pressure (mmHg) 
Other risk factors, 
OD or Disease 
Normal 
SBP 120-129 
or DBP 80-84 
High normal 
SBP 130-139 
or DBP 85-89
Grade 1 HT 
SBP 140-159 
or DBP 90-99
Grade 2 HT 
SBP 160-179 or 
DBP 100-109
Grade 3 HT 
SBP ≥180 
or DBP ≥110
Standardized 
prevalence 
3.8% 
(3 772) 
2.8% 
(2 799) 
1.6% 
(1 645) 
0.2% 
(162) 
0.0% 
(22) No other 
risk factor Follow up 
visits /year 0 0 3 291 324 76 
Standardized 
prevalence 
17.2% 
(17 189) 
16.4% 
(16 366) 
15.1% 
(15 117) 
3.3% 
(3 326) 
0.9% 
(904) 1-2 risk 
factors Follow up 
visits /year 60 161 57 282 30 235 6 652 3 164 
Standardized 
prevalence 
3.6% 
(3 577) 
5.0% 
(5 025) 
10.9% 
(10 925) 
7.2% 
(7 217) 
4.2% 
(4 190) 3 or more risk factors, 
MS, OD or 
Diabetes 
Follow up 
visits /year 12 520 17 587 38 238 25 259 14 665 
Standardized 
prevalence 
0.9% 
(904) 
1.3% 
(1 347) 
2.6% 
(2 642) 
1.9% 
(1 854) 
1.0% 
(1 016) Established 
CV or renal 
disease Follow up 
visits /year 3 163 4 715 9 248 6 490 3 556 Page 6 of 9
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ventional risk factors and medical interventions alone.
Recently, a prestigious, Norwegian study was conducted
on evidence-based implementation of a CVD preventive
guideline in general practice [43,44]. It turned out that
even motivated GPs receiving tailored information,
prompting and feedback showed surprisingly low con-
cordance with the recommendations. This finding accords
well with previous studies in national and international
settings [45,46]. The lack of adherence, as is usually the
case, was interpreted as proof that practicing clinicians are
not 'good enough'. This interpretation may however be
unsatisfactory. An alternative, or additional, interpreta-
tion is that contemporary CVD prevention guidelines are
not good enough, in the sense that they are not in reason-
able concordance with human nature and the realities of
clinical practice [47].
The 2007 guideline's evidence-base contains 825 refer-
ences. None of these discuss how medical professionals
may address societal, political, work-related and rela-
tional factors, which have all been documented to play
significant roles in CVD aetiology and prognosis [47,48].
Gender-specific proportions of individuals within 5-year age groups, labelled at different risk levelsFigure 4
Gender-specific proportions of individuals within 5-year age groups, labelled at different risk levels. Gender-spe-
cific proportions of individuals within 5-year age groups, labelled at different risk levels according to the 2007 Guidelines for 
the Management of Arterial Hypertension [13]: average risk (purple), low added risk (green), moderate added risk (yellow), 
high added risk (orange), and very high added risk (red).Page 7 of 9
(page number not for citation purposes)
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modate such perspectives in clinical guidelines, but ignor-
ing evidence because it fits poorly with the mainstream,
established biomedical understanding of hypertension is
neither scientifically nor morally defendable.
Conclusion
Our findings indicate that the 2007 European blood pres-
sure guidelines have an inherent potential to destabilise
the healthcare system in Norway, one of the world's most
long- and healthy-living nations, by international com-
parison. In our view, such a large-scale, preventive medi-
cal enterprise can only be regarded as scientifically sound
and truly evidence-based, as long as issues of practical fea-
sibility and sustainability are made transparent and dis-
cussed [45].
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